SEC Filings

Form 10-Q
APRICUS BIOSCIENCES, INC. filed this Form 10-Q on 05/03/2018
Document Outline
Entire Document (2773.4 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - Table of Contents
Page 4 - PART I.
Page 5 - Apricus Biosciences, Inc. and Subsidiaries
Page 6 - Apricus Biosciences, Inc. and Subsidiaries
Page 7 - Apricus Biosciences, Inc. and Subsidiaries
Page 8 - Apricus Biosciences, Inc. and Subsidiaries
Page 9 - N/A
Page 10 - Warrant Liabilities
Page 11 - Income (Loss) Per Common Share
Page 12 - Segment Information
Page 13 - Leases
Page 14 - Discontinued Operations
Page 15 - 4. OTHER FINANCIAL INFORMATION
Page 16 - September 2017 Financing
Page 17 - September 2016 Financing
Page 18 - January 2016 Financing
Page 19 - Warrants
Page 20 - MANAGEMENT'S DISCUSSION
Page 21 - Overview
Page 22 - Liquidity, Capital Resources and Financial Condition
Page 23 - N/A
Page 24 - Critical Accounting Estimates and Policies
Page 25 - Results of Operations
Page 26 - Discontinued Operations
Page 27 - Financing Activities from Continuing Operations
Page 28 - Changes in Internal Control over Financial Reporting
Page 29 - the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may a
Page 30 - We expect to continue to require external financing to fund our operations, which may not be availab
Page 31 - We have a history of operating losses and an accumulated deficit, and we may be unable to generate s
Page 32 - If we do not secure collaborations with strategic partners to develop and commercialize our product
Page 33 - If we are unable to adequately establish, maintain and protect our intellectual property rights, we
Page 34 - We face a high degree of competition.
Page 35 - We will need approval from the FDA for our proposed trade names. Any failure or delay associated wit
Page 36 - If we fail to attract and retain senior management and key scientific personnel, we may be unable to
Page 37 - Industry Risks
Page 38 - N/A
Page 39 - Delays in clinical trials are common and have many causes, and if we experience significant delays i
Page 40 - If the FDA does not conclude that certain of our product candidates satisfy the requirements for the
Page 41 - Even if we receive regulatory approval for our product candidates, we will be subject to ongoing reg
Page 42 - Our product candidates may cause undesirable side effects or have other properties that could delay
Page 43 - Our employees, independent contractors, principal investigators, CROs, consultants, commercial partn
Page 44 - Recent U.S. tax legislation may materially adversely affect our financial condition, results of oper
Page 45 - We may issue additional shares of our capital stock that could dilute the value of your shares of co
Page 46 - EXHIBIT
Page 47 - N/A
Page 48 - N/A
Page 49 - N/A
Page 50 - SIGNATURES
Subdocument 2 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 3 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer